Antithrombotics in acute coronary syndromes: updates from the past year
Marc Bonaca1, Robert P Giugliano
1Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA, mbonaca@partners.org.
Insights
Managing acute coronary syndromes is evolving with new potent antiplatelet drugs and oral anticoagulants. Careful patient selection and risk assessment are crucial for optimal treatment and preventing adverse events.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes (ACS) are a significant cause of death and disability.
- Ongoing research yields new therapeutic options for ACS management.
Purpose of the Study:
- To discuss the challenges and considerations for practitioners in selecting optimal ACS treatment regimens.
- To highlight the implications of newer antiplatelet agents and oral anticoagulants.
Main Methods:
- Review of current and emerging therapies for acute coronary syndromes.
- Analysis of risk/benefit profiles for novel antiplatelet and anticoagulant agents.
Main Results:
- Newer antiplatelet agents (prasugrel, ticagrelor) and oral anticoagulants require careful patient selection.
- Risk assessment for ischemic events and bleeding is paramount with these agents.
Conclusions:
- Practitioners face challenges in optimizing ACS treatment due to increased therapeutic options.
- Updated guideline recommendations are essential for navigating complex treatment decisions in ACS.
Opinion Statement:
Acute coronary disease remains a major cause of morbidity and mortality. Investigation in established and novel therapies aimed at treating acute coronary syndromes continues. The resulting increase in available options will present a significant challenge to practitioners determining the optimal regimen for specific patients. The addition of newer, more potent antiplatelet agents, such as prasugrel and possibly ticagrelor, will require careful patient selection and risk assessment for both recurrent ischemic events and bleeding. The likely addition of newer oral anticoagulants will require knowledge as to their specific characteristics and risk/benefit ratios. Incremental updates to guideline recommendations from established expert groups will be important in providing guidance.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Angina IV: Management
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Atherosclerosis III: Management


